UNSPSC 51314326: Brompheniramine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314326 Brompheniramine/phenylpropanolamine is a Commodity code that in practice receives pharmaceutical and over-the-counter product procurements from state and local health agencies, though recent solicitations tagged under this code address a broader range of pharmaceutical sourcing than the specific drug name suggests. State and local governments soliciting under this code include county health departments, state health and human services commissions, and regional cooperative purchasing alliances serving multiple jurisdictions. The work involves establishing supply contracts for generic pharmaceuticals, branded drugs, and OTC products with fixed or negotiated pricing structures, often requiring compliance with federal manufacturing standards (cGMP, DSCSA), E-Verify, drug-free workplace certifications, and insurance coverage thresholds. Contracts typically span two years with optional renewal terms and include quarterly or ongoing delivery schedules to designated health facilities.

Recent activity spans Florida, Texas, and Minnesota-led multistate cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries and FEMA funding compliance. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capability data on direct-to-manufacturer prescription programs for its Therapeutic Pharmacy Initiative, signaling future formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (due March 26, 2026) to establish statewide and multi-state contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and awards effective July 1, 2026. The code shows active procurement across health agencies and cooperative purchasing vehicles but with mismatch between the specific brompheniramine/phenylpropanolamine commodity name and the broader pharmaceutical sourcing reflected in recent solicitations.